- Comprehensive platform integrates established and emerging technologies to create novel RNA medicines with advanced programmability, improved durability, and expanded delivery and tissue breadth
- Expansive therapeutic portfolio initially focused on immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics
- World-class team with extensive track records of RNA and other drug discovery, development, and approvals across multiple modalities and therapeutic areas